Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
| Autor: | Eric Laruelle, Brigit C. van Jaarsveld, Kitty J Jager, Frederic Collart, Helena Rydell, Cécile Couchoud, Aleix Cases, Jamie P. Traynor, Thijs T. Jansz, Jaakko Helve, Mustafa Arici, Ziad A. Massy, Marlies Noordzij, Carmine Zoccali, Anneke Kramer, Bård Waldum-Grevbo |
|---|---|
| Přispěvatelé: | CHU Pontchaillou [Rennes], Agence de la biomédecine [Saint-Denis la Plaine], Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], European Renal Association-European Dialysis and Transplant Association, ERA-EDTA, We would like to thank the patients and the staff of the dialysis and transplant units for contributing the data via their national and regional renal registries. Furthermore, we gratefully acknowledge the following registries and persons for their contributions of data: Austrian Dialysis and Transplant Registry (R. Kramar), French-speaking Belgian Society of Nephrology (J.M. des Grottes), Finnish Registry for Kidney Diseases (P. Finne, A. Pylsy and P.H. Groop), France: The Epidemiology and Information Network in Nephrology (REIN) (M. Lassalle), Norwegian Renal Registry (T. Leivestad, A.V. Reisæter and A. Åsberg), Swedish Renal Registry (K.G. Prütz, M. Stendahl, M. Evans, S. Schön, T. Lundgren and M. Segelmark), Scottish Renal Registry (all of the Scottish renal units), and the regional registry of Catalonia (E. Arcos, J. Comas and J. Tort) and the other ERA-EDTA Registry Committee members not mentioned above for their advice in the analysis and the drafting of this article: P. Ambühl, J. De Meester, M. Evans, P. Finne, J. Harambat, L. Mercadal, M. Nordio, S.S. Sørensen and E. Vidal, and M. Pippias and V.S. Stel in the AMC Registry office for data collection and management. The ERA-EDTA Registry is funded by the ERA-EDTA. This article was written by T. Jansz, M. Noordzij, A. Kramer, E. Laruelle, C. Couchoud, F. Collart, A. Cases, M. Arici, J. Helve, B. Waldum-Grevbo, H. Rydell, J. Traynor, C. Zoccali, Z.A. Massy, K.J. Jager and B.C. van Jaarsveld on behalf of the ERA-EDTA Registry, which is an official body of the ERA-EDTA., HUS Abdominal Center, Department of Medicine, Nefrologian yksikkö, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, APH - Methodology, Nephrology, ACS - Diabetes & metabolism, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM) |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_treatment 030232 urology & nephrology 030204 cardiovascular system & hematology [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology 0302 clinical medicine Registries nocturnal haemodialysis Mortality rate Hazard ratio RENAL REPLACEMENT THERAPY Middle Aged Prognosis DIALYSIS OUTCOMES Hemodiàlisi 3. Good health Europe Survival Rate haemodialysis Nephrology Hemodialysis ERA-EDTA Registry Female PRACTICE PATTERNS INTENSIVE HEMODIALYSIS medicine.medical_specialty survival 03 medical and health sciences MORTALITY RISK Renal Dialysis LEFT-VENTRICULAR MASS Internal medicine medicine Mortalitat Humans Renal replacement therapy Mortality Dialysis Aged Transplantation HOME HEMODIALYSIS CONVENTIONAL HEMODIALYSIS business.industry Proportional hazards model Home hemodialysis KIDNEY-DISEASE Original Articles 3126 Surgery anesthesiology intensive care radiology Confidence interval Kidney Failure Chronic [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie extended-hours business CENTER NOCTURNAL HEMODIALYSIS |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona Nephrology Dialysis Transplantation Nephrology Dialysis Transplantation, Oxford University Press (OUP), 2020, 35 (3), pp.488-495. ⟨10.1093/ndt/gfz208⟩ Jansz, T T, Noordzij, M, Kramer, A, Laruelle, E, Couchoud, C, Collart, F, Cases, A, Arici, M, Helve, J, Waldum-Grevbo, B, Rydell, H, Traynor, J P, Zoccali, C, Massy, Z A, Jager, K J & van Jaarsveld, B C 2020, ' Survival of patients treated with extended-hours haemodialysis in Europe : an analysis of the ERA-EDTA Registry ', Nephrology, Dialysis, Transplantation, vol. 35, no. 3, pp. 488-495 . https://doi.org/10.1093/ndt/gfz208 Nephrology, dialysis, transplantation, 35(3), 488-495. Oxford University Press Nephrology, Dialysis, Transplantation, 35(3), 488-495. Oxford University Press Nephrology Dialysis Transplantation, Oxford University Press, 2020, 35 (3), pp.488-495. ⟨10.1093/ndt/gfz208⟩ |
| ISSN: | 0931-0509 1460-2385 |
| DOI: | 10.1093/ndt/gfz208⟩ |
| Popis: | Background Previous US studies have indicated that haemodialysis with ≥6-h sessions [extended-hours haemodialysis (EHD)] may improve patient survival. However, patient characteristics and treatment practices vary between the USA and Europe. We therefore investigated the effect of EHD three times weekly on survival compared with conventional haemodialysis (CHD) among European patients. Methods We included patients who were treated with haemodialysis between 2010 and 2017 from eight countries providing data to the European Renal Association–European Dialysis and Transplant Association Registry. Haemodialysis session duration and frequency were recorded once every year or at every change of haemodialysis prescription and were categorized into three groups: CHD (three times weekly, 3.5–4 h/treatment), EHD (three times weekly, ≥6 h/treatment) or other. In the primary analyses we attributed death to the treatment at the time of death and in secondary analyses to EHD if ever initiated. We compared mortality risk for EHD to CHD with causal inference from marginal structural models, using Cox proportional hazards models weighted for the inverse probability of treatment and censoring and adjusted for potential confounders. Results From a total of 142 460 patients, 1338 patients were ever treated with EHD (three times, 7.1 ± 0.8 h/week) and 89 819 patients were treated exclusively with CHD (three times, 3.9 ± 0.2 h/week). Crude mortality rates were 6.0 and 13.5/100 person-years. In the primary analyses, patients treated with EHD had an adjusted hazard ratio (HR) of 0.73 [95% confidence interval (CI) 0.62–0.85] compared with patients treated with CHD. When we attributed all deaths to EHD after initiation, the HR for EHD was comparable to the primary analyses [HR 0.80 (95% CI 0.71–0.90)]. Conclusions EHD is associated with better survival in European patients treated with haemodialysis three times weekly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|